Biocon Earmarks Rs 268 Crore for Research After Inking Pact With Mexican Firm

Biocon restructured its legal entities to align with its growth strategies represented by its strategic business units.

Published: 27th April 2016 02:49 PM  |   Last Updated: 27th April 2016 02:49 PM   |  A+A-

BENGALURU: India's largest biopharma firm Biocon Ltd late on Tuesday reported a 250 per cent jump in its met profit during the fourth quarter to Rs 361 crore, and 17 per cent increase in revenue to Rs 1,004 crore.

The very high increase in its profits due to an exceptional income of Rs 268 crore which was an amount Biocon earmarked for research, but has now recognised the amount as income, after it signed a co-development pact for recombinant human (rh) insulin with Laboratorios PiSA SA de CV (PiSA) of Mexico for the US market. But for the exceptional income, profits dropped 54 per cent on provisioning for research and development (R&D). This is the highest so far it has allocated for work on new drugs and biosimilars.

“Biocon’s gross R&D expenses at Rs 152 crore this quarter were the highest till date reflecting the advancement of our innovation led drug pipeline comprising novels, biosimilars and ANDAs. We expect to file a number of regulatory submissions in US and Europe for many of these programs in FY17,” Biocon chairperson and managing director Kiran Mazumdar-Shaw said in a statement.

Biocon has restructured its legal entities to align with its growth strategies represented by its strategic business units.

"We believe this restructuring will enable us to unlock greater value from our business segments at an opportune time. All our biosimilar assets will now be consolidated under the new legal entity, Biocon Biologics Limited incorporated in UK as a subsidiary of Biocon Limited," she added.

Also, during the quarter, Biocon's biosimilar insulin Glargine got approval in Japan and also got the nod in the European Union for it's generic Rosuvastatin Calcium tablets, its first generic formulation in the developed markets. Meanwhile, it expects filings in fiscal 2016-17 after the global Phase III clinical trials for biosimilar Insulin Glargine, Trastuzumab, Pegfilgrastim and Adalimumab.

Stay up to date on all the latest Business news with The New Indian Express App. Download now


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp